Clinical outcome of renal cancer patients who early interrupted immunotherapy due to serious immune-related adverse events. Meet-Uro 13 trial on behalf of the MeetUro investigators

BACKGROUND: Severe immune-related Adverse Events (irAEs) develop in 10–27% of patients treated with Immune-Oncology (IO) [Powles (Lancet 391:748–757, 2018); Galsky (Lancet 395:1547–1557, 2020); Haanen (Ann Oncol 28:119–142, 2017)]. The aim of our study was to evaluate efficacy and clinical outcome o...

Descripción completa

Detalles Bibliográficos
Autores principales: Stellato, Marco, Procopio, Giuseppe, De Giorgi, Ugo, Maruzzo, Marco, Bimbatti, Davide, Mennitto, Alessia, Sbrana, Andrea, Roviello, Giandomenico, Casadei, Chiara, Sepe, Pierangela, Pignata, Sandro, Santini, Daniele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330118/
https://www.ncbi.nlm.nih.gov/pubmed/34344414
http://dx.doi.org/10.1186/s12967-021-03008-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330118/
https://www.ncbi.nlm.nih.gov/pubmed/34344414
http://dx.doi.org/10.1186/s12967-021-03008-9

Ejemplares similares